CHMP approves 11 new drugs, rejects one

Several drugs from Danish developers have been appraised positively by the EMA's expert committee, the CHMP, during its November meeting. In total, 11 drugs have gone through the eye of the needle.


Novo Nordisk, Lundbeck and Ascendis Pharma count among the companies that have cause for celebration after this month's meeting at the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP).

The committee has thus nominated Novo Nordisk's weight loss drug Wegovy, Lundbeck's migraine infusion Vyepti and Ascendis Pharma's growth hormone Skytrofa for European patient use.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs